This double blind, placebo controlled, multi-arm, multi-site study investigates the safety and efficacy of stem cell therapy for the treatment of patients admitted to hospital suffering complications from COVID-19 and the treatment of healthy subjects (healthcare providers) for prophylactic effect following those patients.

Recent preliminary data from Wuhan/China have claimed that intravenous injections of mesenchymal stem cells derived from human umbilical chords have resulted in complete recovery of COVID-19 infected elderly patients with respiratory failure.

This study investigates the efficacy and safety of a single umbilical cord derived stem cell intravenous injection in patients with suspected or confirmed COVID-19 infection with fever and respiratory illness.

A second arm will test efficacy and safety of a single umbilical cord derived stem cell intravenous injection to healthcare providers at high exposure rates to COVID-19 infection.

Inclusion Criteria:

• Age 18 and older
• Ability to provide informed consent

Exclusion Criteria:

• Active or recent malignancy (within last 2 years)
• Inability to provide informed consent
• Current enrollment in any other COVID-19 treatment study

Data will be blinded and password protected. Research publications will be produced for medical journals. Participating Investigators will have password protected access only.